Anbio Biotechnology
NNNN · In Vitro & In Vivo Diagnostic Substances · EDGAR filings ↗
Grade
B79Small, highly profitable IVD diagnostics firm with exceptional reported margins and returns but weak cash conversion and short operating history.
Strengths
- Top-decile gross margin 87% and net margin 74% (100th pct), operating margin 67%
- Strong returns (ROE 21%, ROA 21%, ~65th–95th pct) with healthy net income growth (170%)
- Pristine balance sheet (current/quick ratio 344, ample liquidity headroom)
Risks
- Negative operating cash margin (-78%) signals poor earnings-to-cash conversion
- Short operating history, third-party-dependent supply/distribution, post-COVID revenue normalization
- Sub-scale and reliant on regulatory clearances (IVDR) for sustained growth
Key metrics
Gross margin
87.2%
Operating margin
66.7%
Net margin
74.1%
Return on equity
21.2%
Return on assets
21.2%
Revenue growth (QoQ)
5.6%
Net-income growth
169.9%
Current ratio
344.3×
Tangible book value
$30M
Cash & investments
$12M
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-04-07 | 2025-12-31 | 0001185185-26-001294 ↗ |
| 20-F | 2025-04-28 | 2024-12-31 | 0001213900-25-035802 ↗ |